Get notified when WVE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $16.39 Per Share (new) — New investors will experience substantial immediate dilution in net tangible book value per share.
Wave Life Sciences prices $350M offering at $19/share to fund obesity drug trials
Filed December 11, 2025 · ~1 min read
Key Changes
-
high
Wave Life Sciences is offering 15,789,475 ordinary shares and pre-funded warrants for 2,631,578 shares at $19.00 per share, raising $349,999,744 before expenses.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $328.4 million, or $377.8 million if underwriters fully exercise their option to purchase additional shares.
Use of Proceeds verify on EDGAR → -
high
The company intends to use net proceeds to accelerate Phase 2 clinical trials for WVE-007 (INHBE GalNAc-siRNA) for obesity, and for general corporate purposes.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (INBP 10-K) is open in full — no account needed.
Partner
Trade WVE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify